الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 172 |  |  |
| | | from | 172 | | |
Abstract
Chronic obstructive pulmonary disease (COPD), predominantly prevalent in men, is a chronic inflammatory disorder of the airway and lungs. COPD is one of the most prevalent diseases and the third leading cause of death globally. COPD is a common, preventable, treatable disease that characterize by persistant chest symptoms and airflow limitation due to air way or, and alveolar abnormalities.
Benign prostatic hyperplasia (BPH) is a common medical condition in older male populations. Approximately 14% of men aged 40–49 years are estimated to have BPH, and the prevalence increases to >50% in men aged 60 years and over.
COPD and BPH are associated with chronic inflammation of the airway and prostate, respectively, and are common disorders in ageing male populations COPD is associated with increased risk of BPH.
Judging from the association between COPD and BPH in ageing male population, and the samilarities between receptors in airways and the urinary bladder, we made our study for showing the effect of treatment of male lower urinary tract symptoms by either tamsulin alone or the combination of tamsulin and sofenacin, on the airways of COPD patients by spirometric assessment before and after starting treatment of BPH.
The present study was conducted upon 60 subjects during the period from March 2019 to August 2019 who were admitted to our chest and urology department or outpatient clinics visitors, to Ain Sham University Hospitals.
We made our study on 60 male patients and divided them into two groups, all 60 patients were copd patients on active treatment with symptomatic benign prostatic hyperplasia, first group 30 patients is receiving tamsulosin only, mean age was 62.4 years, mean prostate size 35 and mean mMRC of 3.7 and the second group 30 patients received tamsulosin and sofencin, mean age of 58.8 mean prostate size of 32.7 and mean mMRC of 3.7. spirometric assessment for all patient before starting treatment and follow up was done after one month and while the patient on his treatment.
In first group, there was significant improvement in FVC. Mean FVC pretreatment was 2.22 and mean FVC posttreatment was 2.42.There was significant improvement in FEV1. Mean FEV1 pretreatment was 1.17 and posttreatment was 1.24.
In second group, there was significant improvement in FVC. Mean FVC pretreatment was 2.40 and mean FVC posttreatment was 2.56. There was significant improvement in FEV1. Mean FEV1 pretreatment was 1.25 and posttreatment was 1.38,
By comparison of the two groups, there was non significant change. As regard percent of change of FVC, first group’s median was 7.9% and second group median was 5.6%. As regard percent of change of FEV1, in first group’s median was 5.7% and second group’s median was 7.4%.